389 related articles for article (PubMed ID: 35095993)
1. RNA N6-Methyladenosine Regulators Contribute to Tumor Immune Microenvironment and Have Clinical Prognostic Impact in Breast Cancer.
Mu LX; Shao YC; Wei L; Chen FF; Zhang JW
Front Genet; 2021; 12():650499. PubMed ID: 35095993
[No Abstract] [Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
4. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
5. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
6. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
7. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
8. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
9. Characterization of ligamentum flavum hypertrophy based on m6A RNA methylation modification and the immune microenvironment.
He Z; Zhu Z; Tang T; Guo P; Gao M; Li B; Nguyen TCT; Chen H; Liu X; Zhou Z; Liu S
Am J Transl Res; 2022; 14(12):8800-8827. PubMed ID: 36628248
[TBL] [Abstract][Full Text] [Related]
10. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
11. m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor.
Cong R; Ji C; Zhang J; Zhang Q; Zhou X; Yao L; Luan J; Meng X; Song N
Transl Androl Urol; 2021 Feb; 10(2):662-679. PubMed ID: 33718069
[TBL] [Abstract][Full Text] [Related]
12. The hub ten gene-based risk score system using RNA m
Yuan B; Liu W; Huo M; Zhang J; Yang Y; Gao T; Yin X; Yang T; Teng X; Huang W; Yu H
Breast Cancer; 2022 Jul; 29(4):645-658. PubMed ID: 35174450
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
14. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtype identification and predictive power of N6-methyladenosine regulator in unexplained recurrent pregnancy loss.
Huo J; Chen Q; Zhang Y; Li N; Fu Z; Ma N; Zheng N; Cui N; Li L
Front Genet; 2022; 13():925652. PubMed ID: 36118846
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of N6-methylandenosine regulators and m6A-related RNAs as prognosis factors in colorectal cancer.
Li W; Gao Y; Jin X; Wang H; Lan T; Wei M; Yan W; Wang G; Li Z; Zhao Z; Jiang X
Mol Ther Nucleic Acids; 2022 Mar; 27():598-610. PubMed ID: 35070494
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of prognostic prediction established on N6-methyladenosine related genes in cervical squamous cell carcinoma.
Chen D; Guo W; Yu H; Yang J
Transl Cancer Res; 2022 Sep; 11(9):3064-3079. PubMed ID: 36237271
[TBL] [Abstract][Full Text] [Related]
18. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
19. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
Front Genet; 2021; 12():790888. PubMed ID: 34976022
[TBL] [Abstract][Full Text] [Related]
20. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
[Next] [New Search]
